Literature DB >> 16020751

Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo.

Maura Camozzi1, Serena Zacchigna, Marco Rusnati, Daniela Coltrini, Genaro Ramirez-Correa, Barbara Bottazzi, Alberto Mantovani, Mauro Giacca, Marco Presta.   

Abstract

OBJECTIVE: The fibroblast growth factor (FGF)/FGF receptor system plays an important role in smooth muscle cell (SMC) activation. Long-pentraxin 3 (PTX3) is a soluble pattern recognition receptor with non-redundant functions in inflammation and innate immunity. PTX3 is produced by different cell types of the vessel wall, including SMCs. PTX3 binds FGF2 and inhibits its angiogenic activity on endothelial cells. We investigated the capacity of PTX3 to affect FGF2-dependent SMC activation in vitro and in vivo. METHODS AND
RESULTS: When added to human coronary artery SMCs, human PTX3 inhibits cell proliferation driven by endogenous FGF2 and the mitogenic and chemotactic activity exerted by exogenous recombinant FGF2. Accordingly, PTX3 prevents (125)I-FGF2 interaction with FGF receptors on the same cells. Also, PTX3 overexpression after recombinant adeno-associated virus-PTX3 gene transfer inhibits human coronary artery SMC proliferation and survival promoted by FGF2 in vitro. Consistently, a single local endovascular injection of recombinant adeno-associated virus-PTX3 gene inhibits intimal thickening after balloon injury in rat carotid arteries.
CONCLUSIONS: PTX3 is a potent inhibitor of the autocrine and paracrine stimulation exerted by FGF2 on SMCs. Local PTX3 upregulation may modulate SMC activation after arterial injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020751     DOI: 10.1161/01.ATV.0000177807.54959.7d

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  29 in total

1.  Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study.

Authors:  Ruth Dubin; Yongmei Li; Joachim H Ix; Michael G Shlipak; Mary Whooley; Carmen A Peralta
Journal:  Am Heart J       Date:  2012-02       Impact factor: 4.749

Review 2.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

3.  The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2.

Authors:  Antonio Inforzato; Clair Baldock; Thomas A Jowitt; David F Holmes; Ragnar Lindstedt; Marcella Marcellini; Vincenzo Rivieccio; David C Briggs; Karl E Kadler; Antonio Verdoliva; Barbara Bottazzi; Alberto Mantovani; Giovanni Salvatori; Anthony J Day
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

4.  Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile.

Authors:  Michela Zanetti; Alessandra Bosutti; Clara Ferreira; Pierandrea Vinci; Gianni Biolo; Maurizio Fonda; Matteo Valente; Luigi Cattin; Gianfranco Guarnieri; Rocco Barazzoni
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

5.  Apolipoprotein A-I inhibits LPS-induced atherosclerosis in ApoE(-/-) mice possibly via activated STAT3-mediated upregulation of tristetraprolin.

Authors:  Kai Yin; Shi-lin Tang; Xiao-hua Yu; Guang-hui Tu; Rong-fang He; Jin-feng Li; Di Xie; Qing-jun Gui; Yu-chang Fu; Zhi-sheng Jiang; Jian Tu; Chao-ke Tang
Journal:  Acta Pharmacol Sin       Date:  2013-04-08       Impact factor: 6.150

Review 6.  Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3.

Authors:  Alberto Mantovani; Cecilia Garlanda; Andrea Doni; Barbara Bottazzi
Journal:  J Clin Immunol       Date:  2007-09-09       Impact factor: 8.317

7.  Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis.

Authors:  Daria Leali; Antonio Inforzato; Roberto Ronca; Roberta Bianchi; Mirella Belleri; Daniela Coltrini; Emanuela Di Salle; Marina Sironi; Giuseppe Danilo Norata; Barbara Bottazzi; Cecilia Garlanda; Anthony J Day; Marco Presta
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-01-19       Impact factor: 8.311

8.  Pentraxin 3 (PTX3) expression in allergic asthmatic airways: role in airway smooth muscle migration and chemokine production.

Authors:  Jingbo Zhang; Lianyu Shan; Latifa Koussih; Naresh Singh Redhu; Andrew J Halayko; Jamila Chakir; Abdelilah S Gounni
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

9.  PTX3 Effects on Osteogenic Differentiation in Osteoporosis: An In Vitro Study.

Authors:  Chiara Greggi; Ida Cariati; Federica Onorato; Riccardo Iundusi; Manuel Scimeca; Umberto Tarantino
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

10.  Efficacy of procalcitonin and pentraxin-3 as early biomarkers for differential diagnosis of pleural effusions.

Authors:  Anita Sharma; Apurva Agrawal; Girish Sindhwani; Ashish Sharma; Sojit Tomo; Jaykaran Charan; Dharmveer Yadav; Praveen Sharma
Journal:  Pleura Peritoneum       Date:  2021-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.